• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于粪便免疫化学检测的筛查项目中的间隔期结直肠癌

Interval Colorectal Cancers in a Fecal Immunochemical Test-Based Screening Program.

作者信息

Hsu Wen-Feng, Ladabaum Uri, Su Chiu-Wen, Hsu Chen-Yang, Yen Amy Ming-Fang, Chen Sam Li-Sheng, Hsu Tsui-Hsia, Lin Li-Ju, Lee Yi-Chia, Wu Ming-Shiang, Chen Hsiu-Hsi, Chiu Han-Mo

机构信息

Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California.

出版信息

JAMA Netw Open. 2025 Jul 1;8(7):e2523441. doi: 10.1001/jamanetworkopen.2025.23441.

DOI:10.1001/jamanetworkopen.2025.23441
PMID:40720124
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12305388/
Abstract

IMPORTANCE

Interval colorectal cancers (CRCs) can occur after a negative result on a primary screening test or after a colonoscopy for a positive screening test result without the diagnosis of CRC.

OBJECTIVE

To compare the burden, incidence, mortality, and long-term survival of interval CRC after a fecal immunochemical test (post-FIT interval CRC) and colonoscopy (postcolonoscopy interval CRC) in the FIT-based Taiwan CRC Screening Program.

DESIGN, SETTING, AND PARTICIPANTS: This cohort study analyzed participants (aged 50-74 years) in the Taiwan CRC Screening Program who completed at least 1 FIT between January 1, 2004, and December 31, 2012. Two cohorts were created: one including individuals with a negative FIT result, and the other comprising individuals with a positive FIT result followed by a negative colonoscopy result. Post-FIT interval CRC or postcolonoscopy interval CRC and their survival status were identified and verified via linkage to Taiwan Cancer Registry and Taiwan Death Registry through December 31, 2019. Data analysis was performed between January 2004 and December 2019.

EXPOSURES

Participants were screened using FIT, with follow-up colonoscopy offered to individuals who tested positive. The main exposures of interest were (1) negative FIT vs positive FIT result with a negative colonoscopy result, and (2) negative FIT and positive FIT results with a negative colonoscopy result further stratified by hospital-level adenoma detection rate (ADR). Low was defined as less than 40% ADR, middle was between 40% and less than 65% ADR, and high was 65% or higher ADR.

MAIN OUTCOMES AND MEASURES

The primary outcomes were the incidence, CRC-specific mortality, and survival rates for post-FIT interval CRC and postcolonoscopy interval CRC.

RESULTS

A total of 4018 patients with interval CRC (mean [SD] age at diagnosis, 62.8 [5.9] years; 2118 males [52.7%]) were included in the analysis. Among 15 386 total CRCs in the program, 10 515 (68.3%) were screen-detected CRCs and 4018 (26.2%) were interval CRCs. Of these interval CRC cases, 2782 (18.1%) were post-FIT interval CRCs and 1236 (8.1%) were postcolonoscopy interval CRCs. Compared with post-FIT interval CRC detected after a negative FIT result, postcolonoscopy interval CRC incidence (0.75 [95% CI, 0.71-0.79] per 1000 person-years vs 0.09 [95% CI, 0.09-0.10] per 1000 person-years) and mortality (0.12 [95% CI, 0.11-0.14] per 1000 person-years vs 0.02 [95% CI, 0.02-0.03] per 1000 person-years) after follow-up colonoscopy were higher, with adjusted hazard ratios (AHRs) of 7.06 (95% CI, 6.35-7.57) and 5.04 (95% CI, 4.33-5.85), respectively. Hospital-level ADR was inversely associated with postcolonoscopy interval CRC incidence (high- vs low-ADR group AHR, 0.26; 95% CI, 0.20-0.36) and mortality (AHR, 0.28; 95% CI, 0.19-0.41). However, among patients with postcolonoscopy interval CRC, CRC-specific death was higher in the high-ADR vs low-ADR setting (AHR, 1.89; 95% CI, 1.04-3.43).

CONCLUSIONS AND RELEVANCE

This cohort study found that interval CRC incidence and mortality were higher after follow-up colonoscopy than after negative FIT result, which suggests that individuals with a positive FIT result undergoing a colonoscopy exhibit a much higher risk for CRC. Survival after the diagnosis of CRC in the high-ADR subgroup was worse, suggesting a ceiling effect for current colonoscopic techniques and highlighting a possible interplay between procedural and biological factors.

摘要

重要性

间期结直肠癌(CRC)可在初次筛查试验结果为阴性后发生,或在结肠镜检查筛查试验结果为阳性但未诊断出CRC之后发生。

目的

在基于粪便免疫化学检测(FIT)的台湾结直肠癌筛查项目中,比较粪便免疫化学检测后间期CRC(FIT后间期CRC)和结肠镜检查后间期CRC(结肠镜检查后间期CRC)的负担、发病率、死亡率和长期生存率。

设计、设置和参与者:这项队列研究分析了台湾结直肠癌筛查项目中年龄在50 - 74岁之间、在2004年1月1日至2012年12月31日期间至少完成1次FIT的参与者。创建了两个队列:一个队列包括FIT结果为阴性的个体,另一个队列包括FIT结果为阳性且随后结肠镜检查结果为阴性的个体。通过与台湾癌症登记处和台湾死亡登记处建立联系,确定并验证FIT后间期CRC或结肠镜检查后间期CRC及其生存状态,截至2019年12月31日。数据分析在2004年1月至2019年12月期间进行。

暴露因素

使用FIT对参与者进行筛查,对检测呈阳性的个体提供后续结肠镜检查。主要关注的暴露因素为:(1)FIT结果为阴性与FIT结果为阳性且结肠镜检查结果为阴性,以及(2)FIT结果为阴性和FIT结果为阳性且结肠镜检查结果为阴性,并根据医院层面的腺瘤检出率(ADR)进一步分层。低ADR定义为低于40%,中ADR定义为40%至低于65%,高ADR定义为65%或更高。

主要结局和测量指标

主要结局为FIT后间期CRC和结肠镜检查后间期CRC的发病率、CRC特异性死亡率和生存率。

结果

共有4018例间期CRC患者(诊断时的平均[标准差]年龄为62.8[5.9]岁;2118例男性[52.7%])纳入分析。在该项目的15386例结直肠癌中,10515例(68.3%)为筛查发现的结直肠癌,4018例(26.2%)为间期结直肠癌。在这些间期CRC病例中,2782例(18.1%)为FIT后间期CRC,1236例(8.1%)为结肠镜检查后间期CRC。与FIT结果为阴性后检测到的FIT后间期CRC相比,结肠镜检查后间期CRC的发病率(每1000人年0.75[95%CI,0.71 - 0.79] vs每1000人年0.09[95%CI,0.09 - 0.10])和死亡率(每1000人年0.12[95%CI,0.11 - 0.14] vs每1000人年0.02[95%CI,0.02 - 0.03])更高,调整后的风险比(AHR)分别为7.06(95%CI,6.35 - 7.57)和5.04(95%CI,4.33 - 5.85)。医院层面的ADR与结肠镜检查后间期CRC的发病率(高ADR组与低ADR组AHR,0.26;95%CI,0.20 - 0.36)和死亡率(AHR,0.28;95%CI,0.19 - 0.41)呈负相关。然而,在结肠镜检查后间期CRC患者中,高ADR组的CRC特异性死亡高于低ADR组(AHR,1.89;95%CI,1.04 - 3.43)。

结论和相关性

这项队列研究发现,结肠镜检查后的间期CRC发病率和死亡率高于FIT结果为阴性后的情况,这表明FIT结果为阳性且接受结肠镜检查的个体患CRC的风险要高得多。高ADR亚组中CRC诊断后的生存率较差,这表明当前结肠镜检查技术存在上限效应,并突出了操作因素和生物学因素之间可能的相互作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b929/12305388/191398984de3/jamanetwopen-e2523441-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b929/12305388/4385f3ccae94/jamanetwopen-e2523441-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b929/12305388/406d3c5462dd/jamanetwopen-e2523441-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b929/12305388/191398984de3/jamanetwopen-e2523441-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b929/12305388/4385f3ccae94/jamanetwopen-e2523441-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b929/12305388/406d3c5462dd/jamanetwopen-e2523441-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b929/12305388/191398984de3/jamanetwopen-e2523441-g003.jpg

相似文献

1
Interval Colorectal Cancers in a Fecal Immunochemical Test-Based Screening Program.基于粪便免疫化学检测的筛查项目中的间隔期结直肠癌
JAMA Netw Open. 2025 Jul 1;8(7):e2523441. doi: 10.1001/jamanetworkopen.2025.23441.
2
Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals.基于愈创木脂的粪便潜血试验与粪便免疫化学试验用于一般风险人群结直肠癌筛查。
Cochrane Database Syst Rev. 2022 Jun 6;6(6):CD009276. doi: 10.1002/14651858.CD009276.pub2.
3
Optimal Stopping Ages for Colorectal Cancer Screening.结直肠癌筛查的最佳停止年龄。
JAMA Netw Open. 2024 Dec 2;7(12):e2451715. doi: 10.1001/jamanetworkopen.2024.51715.
4
Centralized Colorectal Cancer Screening Outreach in Federally Qualified Health Centers: A Randomized Clinical Trial.在联邦合格健康中心开展集中结直肠癌筛查外展活动:一项随机临床试验。
JAMA Netw Open. 2024 Nov 4;7(11):e2446693. doi: 10.1001/jamanetworkopen.2024.46693.
5
Colorectal cancer incidence following a negative colonoscopy in fecal immunochemical test-based screening: a nationwide cohort study after 8 years of screening in Denmark.基于粪便免疫化学检测的筛查中结肠镜检查结果为阴性后的结直肠癌发病率:丹麦8年筛查后的全国队列研究
Endoscopy. 2025 Aug;57(8):864-873. doi: 10.1055/a-2551-1471. Epub 2025 Mar 21.
6
The Impact of Follow-up Colonoscopy on Survival in a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program: A Nationwide Study.基于粪便免疫化学检测的结直肠癌筛查项目中结肠镜随访对生存的影响:一项全国性研究
Dis Colon Rectum. 2025 Jul 1;68(7):899-906. doi: 10.1097/DCR.0000000000003771. Epub 2025 Apr 9.
7
Screening outcomes at second FIT screening in individuals with a first time negative FIT-result or low-risk adenomas: Results from a nationwide FIT screening program.首次粪便免疫化学试验(FIT)结果为阴性或低风险腺瘤患者第二次FIT筛查的结果:一项全国性FIT筛查项目的结果
Int J Cancer. 2025 Aug 15;157(4):698-708. doi: 10.1002/ijc.35419. Epub 2025 Mar 28.
8
The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design.多靶点粪便免疫化学试验与粪便免疫化学试验用于结直肠癌筛查项目:一项具有配对设计的横断面干预研究。
BMC Cancer. 2022 Dec 12;22(1):1299. doi: 10.1186/s12885-022-10372-2.
9
Pooled rates of adenoma detection by colonoscopy in asymptomatic average-risk individuals with positive fecal immunochemical test: a systematic review and meta-analysis.结肠镜检查在粪便免疫化学试验阳性的无症状一般风险个体中检测腺瘤的 pooled 率:系统评价和荟萃分析。
Gastrointest Endosc. 2022 Aug;96(2):208-222.e14. doi: 10.1016/j.gie.2022.04.004. Epub 2022 Apr 9.
10
Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis.粪便免疫化学检测用于在初级保健中对有下腹部症状的患者进行分流,以确定是否需要转诊疑似结直肠癌患者:一项系统评价和成本效益分析。
Health Technol Assess. 2017 May;21(33):1-234. doi: 10.3310/hta21330.

本文引用的文献

1
Lead Time and Immortal Time Biases Impact the Calculation of Post-colonoscopy Colorectal Cancer Survival.检测后结直肠癌生存时间的计算受到导时和永生时间偏倚的影响。
Clin Gastroenterol Hepatol. 2024 Dec;22(12):2529-2531.e7. doi: 10.1016/j.cgh.2024.05.014. Epub 2024 May 21.
2
Adenoma Detection Rate and Colorectal Cancer Risk in Fecal Immunochemical Test Screening Programs : An Observational Cohort Study.粪便免疫化学检测筛查项目中的腺瘤检出率与结直肠癌风险:一项观察性队列研究
Ann Intern Med. 2023 Mar;176(3):303-310. doi: 10.7326/M22-1008. Epub 2023 Feb 21.
3
The Prognostic Utilities of DNA Mismatch Repair Status and KRAS and BRAF Mutation in Korean Colorectal Cancer Patients: The KASID Multicenter Study.
韩国结直肠癌患者中 DNA 错配修复状态和 KRAS 及 BRAF 突变的预后价值:KASID 多中心研究。
Oncology. 2023;101(1):49-58. doi: 10.1159/000527285. Epub 2022 Oct 3.
4
Adenoma Detection Rate and Risk for Interval Postcolonoscopy Colorectal Cancer in Fecal Immunochemical Test-Based Screening : A Population-Based Cohort Study.基于粪便免疫化学试验的筛查中腺瘤检出率和结肠镜检查后结直肠癌的间隔期风险:一项基于人群的队列研究。
Ann Intern Med. 2022 Oct;175(10):1366-1373. doi: 10.7326/M22-0301. Epub 2022 Sep 27.
5
Association of Physician Adenoma Detection Rates With Postcolonoscopy Colorectal Cancer.腺瘤检出率与结肠镜检查后结直肠癌的关系。
JAMA. 2022 Jun 7;327(21):2114-2122. doi: 10.1001/jama.2022.6644.
6
Serrated polyp detection and risk of interval post-colonoscopy colorectal cancer: a population-based study.锯齿状息肉检测与结肠镜检查后结直肠癌间隔期风险:基于人群的研究。
Lancet Gastroenterol Hepatol. 2022 Aug;7(8):747-754. doi: 10.1016/S2468-1253(22)00090-5. Epub 2022 May 9.
7
Long-term effectiveness of faecal immunochemical test screening for proximal and distal colorectal cancers.粪便免疫化学试验筛查近端和远端结直肠癌的长期效果。
Gut. 2021 Dec;70(12):2321-2329. doi: 10.1136/gutjnl-2020-322545. Epub 2021 Jan 25.
8
Randomised comparison of postpolypectomy surveillance intervals following a two-round baseline colonoscopy: the Japan Polyp Study Workgroup.两轮基线结肠镜检查后息肉切除术后监测间隔的随机对照比较:日本息肉研究工作组
Gut. 2020 Nov 2;70(8):1469-78. doi: 10.1136/gutjnl-2020-321996.
9
Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2020.结肠镜息肉切除术后监测:欧洲胃肠道内镜学会(ESGE)指南-2020 年更新。
Endoscopy. 2020 Aug;52(8):687-700. doi: 10.1055/a-1185-3109. Epub 2020 Jun 22.
10
Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer.结肠镜检查和息肉切除术后的随访建议:美国结直肠癌多学会特别工作组的共识更新
Gastroenterology. 2020 Mar;158(4):1131-1153.e5. doi: 10.1053/j.gastro.2019.10.026. Epub 2020 Feb 7.